

INSTITUTIONAL REVIEW BOARD

Application for Initial Protocol Submission

<p>INSTRUCTIONS: Your application includes this form and all documents as defined in ARMC-IRB Guidelines for Principal Investigator of which you have been provided a copy. Answer all questions in the application form. Do not answer questions with "see protocol." Failure to properly complete this application and provide the supporting documents will delay the review and approval of your protocol by the ARMC-IRB.</p>	<p style="text-align: center;">FOR IRB OFFICE USE ONLY</p> <p>Type of Review: <input type="checkbox"/> Full Board <input type="checkbox"/> Expedite <input type="checkbox"/> Exempt</p> <p>IRB Protocol #: _____</p>
---	---

PART A – TITLE/ INVESTIGATOR/ COORDINATOR INFORMATION

Title of Protocol:

Principal Investigator -

Name:	Hospital/Department:
Phone Number:	Mailing Address:
E-mail Address:	

Sub-Investigator(s) -

If more than one, attach separate sheet listing all

Name:	Hospital/Department:
Phone Number:	Mailing Address:
E-Mail Address:	

Research Coordinator -

Name:	Hospital/Department:
Phone Number:	Mailing Address:
E-Mail Address:	

☐ Additional Sub-Investigators (see Attachment A)

PART B – LEVEL OF RISK

Level of Risk: ☐ Minimal ☐ Moderate ☐ High

PART C – SOURCE OF FUNDING/ SPONSOR*Indicate all applicable sources of funding and the sponsor*

- | | |
|--|-------|
| <input type="checkbox"/> Federal Sponsor (FDA, NIH, etc.) | Name: |
| <input type="checkbox"/> Commercial Sponsor (Pharmaceutical, Device, etc.) | Name: |
| <input type="checkbox"/> Foundation Sponsor | Name: |
| <input type="checkbox"/> Other (specify) | Name: |
| <input type="checkbox"/> No support / Internal ARMC project | |

PART D – CONFLICT OF INTEREST

Does the principal investigator or any sub-investigator (or any member of their immediate family) -

- a. Function as an employee, advisor, officer, director, consultant, or other paid position for any listed sponsor? ☐ Yes ☐ No (if yes, see Attachment B)
- b. Receive income (monies paid for services rendered) or non-financial support (drugs, equipment, travel expenses, administrative support, etc.)? ☐ Yes ☐ No (if yes, see Attachment B)
- c. Hold equity interest (stocks) in any listed commercial sponsor? ☐ Yes ☐ No (if yes, see Attachment B)
- d. Have a loan arrangement with any listed sponsor? ☐ Yes ☐ No (if yes, see Attachment B)
- e. Have intellectual property (patents, copyrights, and/or royalties) relevant to the study? ☐ Yes ☐ No (if yes, see Attachment B)

PART E – RECRUITMENT INFORMATION**Subject Matter - Check all that apply**

- | | |
|---|-------|
| <input type="checkbox"/> Investigational New Drug | IND # |
| <input type="checkbox"/> Investigational New Device | IDE # |
| <input type="checkbox"/> Marketed Drug, New Indication | |
| <input type="checkbox"/> Marketed Drug, Approved Indication | |
| <input type="checkbox"/> Non-drug Study | |

Duration of study: # ☐ Months ☐ YearsWill you be advertising? ☐ Yes* ☐ No**If yes, please attach a sample of the advertisement.***Subjects Involved - Check all that apply**

Subjects	Number	Age Range
<input type="checkbox"/> Healthy (normal) Subjects		
<input type="checkbox"/> Patients		

Classification - Check all that apply

- | | | |
|---|---|---|
| <input type="checkbox"/> Adults | <input type="checkbox"/> Physically Handicapped | <input type="checkbox"/> Cognitively Impaired |
| <input type="checkbox"/> Minors (< 18yrs) | <input type="checkbox"/> Pregnant Women | <input type="checkbox"/> Comatose |
| <input type="checkbox"/> Male | <input type="checkbox"/> Non-English Speaking: | <input type="checkbox"/> Prisoners * |
| <input type="checkbox"/> Female | Specify- | *Record Review Only |

Degree of involvement of subjects - Check all that apply

- | | |
|--|---|
| <input type="checkbox"/> Experimentation | <input type="checkbox"/> Medical Record |
| <input type="checkbox"/> Observation | <input type="checkbox"/> Other (specify): |

Source of subjects - Check all that apply

- | | |
|---|---|
| <input type="checkbox"/> ARMC In-Patient | <input type="checkbox"/> ARMC Emergency Dept |
| <input type="checkbox"/> ARMC Out-Patients | <input type="checkbox"/> County/State Public Health |
| <input type="checkbox"/> Other (specify): transfers | |

PART F – CHECKLIST FOR APPLICATION - *protocol submission contains the following:*

- | | |
|---|--|
| <input type="checkbox"/> Study Objectives | <input type="checkbox"/> Degree of Human Subject Involvement |
| <input type="checkbox"/> Background | <input type="checkbox"/> Informed Consent (as applicable) |
| <input type="checkbox"/> Study Design | <input type="checkbox"/> Confidentiality statement |

PART G – APPROVALS: CLINICAL

“I have read ARMC-IRB Investigator Guidelines and signed the Principal Investigator’s Statement of Assurance”

Principal Investigator

Date

“This protocol has been reviewed for scientific merit and has the academic endorsement of this department.”

Department Chair

Date

ARROWHEAD REGIONAL MEDICAL CENTER
INSTITUTIONAL REVIEW BOARD

Principal Investigator Statement of Assurance

By signing below I agree/certify that:

- I have reviewed this protocol submission and agree to accept responsibility for the scientific conduct of this project.
- I will conduct this research in strict compliance with all Federal and/or State Regulations and ARMC-IRB standard operating procedures.
- **I will ensure that all sub-investigators and other study personnel assisting in this research are fully educated as to the entire protocol and consent process as well as data and record keeping requirements.**
- I will not enroll any individual into this research study until I have received final approval in writing from the ARMC-IRB or at any period of time where renewal approval has expired or enrollment has been suspended by either the ARMC-IRB or the study sponsor.
- I will submit any additions, corrections or modifications to the full protocol or the informed consent document to the ARMC-IRB for approval before implementing them.
- I will promptly report to the IRB, any serious adverse reactions, events, complications, or protocol deviations which may occur as a result of this study.
- I will respond promptly to all requests for information or materials from the ARMC-IRB or the IRB Office and will submit annual progress reports in a timely manner for ARMC-IRB renewal approval. It is understood *Exempt* approval expires one year from the date of approval.
- I will not enroll any individual into this research study until such time that I obtain his/her written informed consent, or, if applicable, that of his/her authorized representative.

Principal Investigator Name:

Signature

Date